Skip to main content

Qiagen inks $191M deal to buy infection test panel firm STAT-Dx – FierceBiotech

By February 5, 2018News
qiagen logo

qiagen-logo

Qiagen has agreed to a $191 million deal to acquire STAT-Dx. The takeover will give Qiagen control of a pipeline of assay panels designed to diagnose infections affecting the respiratory and gastrointestinal systems. 

{iframe}https://www.fiercebiotech.com/medtech/qiagen-inks-191m-deal-to-buy-infection-test-panel-firm-stat-dx{/iframe}

Leave a Reply

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.